Boston Scientific (BSX) Asset Writedowns and Impairment (2010 - 2025)

Boston Scientific has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $51.0 million in Q4 2025.

• Asset Writedowns and Impairment for Q4 2025 came in at $51.0 million, down 53.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $188.0 million (up 69.37% YoY), and the FY2025 annual result was $124.0 million, down 67.88% from the prior year.
• Asset Writedowns and Impairment grew to $51.0 million in Q4 2025, from $27.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $197.0 million in Q4 2021 and troughed at $1.0 million in Q3 2023.
• A 5-year average of $85.5 million and a median of $80.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• The widest annual swing landed in 2021, when Asset Writedowns and Impairment jumped 143.21%; it then slumped 99.2% in 2023.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $197.0 million in 2021, then sank by 36.55% to $125.0 million in 2022, then tumbled by 99.2% to $1.0 million in 2023, then jumped by 10900.0% to $110.0 million in 2024, then tumbled by 53.64% to $51.0 million in 2025.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $51.0 million in Q4 2025, $27.0 million in Q3 2025, and $110.0 million in Q4 2024.